Share This

Related Topics News - Drugs

     
 < Previous page   Detail   |   Print    Next page > 
     
《大行》華泰證券降國藥控股目標價至22.54元 維持「買入」評級
2025-04-02T  
《大行》匯豐研究降國藥控股目標價至18元 維持「持有」評級
2025-03-31T  
《業績》神威藥業去年純利8.4億人幣跌13.4% 派第一次中期股息每股36分
2025-03-28T  
《大行》高盛降國藥目標價至18.93元 上季業績遜利潤率續承壓
2025-03-26T  
《大行》瑞銀降國藥目標價至24.5元 對今年增長審慎樂觀
2025-03-26T  
《大行》大華繼顯維持國藥「沽售」評級 料經營前景仍充滿挑戰
2025-03-25T  
國務院:加快推進中藥產業轉型升級 完善中藥材價格監管機制
2025-03-20T  
《港股》恆指高收595點 科指漲近4% 百度漲12%
2025-03-18T  
《大行》大摩:金斯瑞全球本地化發展助增長 重申「增持」評級
2025-03-17T  
《大行》高盛降金斯瑞目標價至27.34元 去年銷售額達指引下限
2025-03-13T  
 < Previous page    Next page > 

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2025 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.